Skip to content 
- [PRESSWIRE] Nottingham, UK – June 4th, 2024 — 4D Medicine Limited has appointed Dr Tom Buckland as its new Chairman and Non-executive Director.
- [PRESSWIRE] Vienna, Austria – 02.05.2003 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).
- [PRESSWIRE] Austria – 04.07.22 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).
- [PRESSWIRE] Asia – 03.05.22 — In South Korea, in cooperation with Heavenly Culture, World Peace and Restoration of Light (HWPL), 18,000 members of Shincheonji Church of Jesus and HWPL participated in blood donation for two weeks from April 18th. This number was recorded as the largest group blood donation in the country.
- [PRESSWIRE] LUBBOCK, TX — April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.
- [PRESSWIRE] Vienna – 23rd February 2022 — Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).
- • Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants • Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening • A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance
- [PRESSWIRE] Austria – 10.12.21 — CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).
- [PRESSWIRE] Austria – 04 May, 2021 — CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.
- [PRESSWIRE] Vienna, Austria – 17 February, 2021 — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.
- The Stragen group announced today the enrollment of the first subject to participate in a Phase IIa study of STR-324…
- [PRESSWIRE] Madrid, Spain – 25 January, 2021 — An innovative new technology from Necenti Labs offers 96% accuracy for COVID-19 detection before infection with deep data to give companies and individuals the power of knowledge to battle lockdown.
- [PRESSWIRE] Denmark – 14 December, 2020 — Many challenges are associated with the conventional eye drop bottle. The global ophthalmic industry has long pushed for a way to better deliver medication to the eye. Now, the Danish-based MedTech start-up, EYE-GO, has the solution that can improve the lives of millions of people globally suffering from dry eyes and other chronic eye conditions. Leading ophthalmologists and frontrunning international players in the industry have already named it “a true game-changer in eye care”. The Danish state participated in the latest funding round.
- [PRESSWIRE] Austria – 19.11.20 — Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).
- [PRESSWIRE] UK – 18.11.20 — Hundreds of religious leaders from around the world gather to pray for the end of COVID-19 ahead of a group plasma donation by 4,000 Shincheonji members…
- [PRESSWIRE] Austria – 24 September, 2020 — Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity study in Europe.
- [PRESSWIRE] Israel – 13 August, 2020 — Kanabo Research LTD und Simply Green BV haben eine exklusive Vertriebsvereinbarung unterzeichnet, um die medizinische Verdampfungstechnologie von Kanabo auf den deutschen Markt zu bringen. Im Rahmen der Vereinbarung erhält Simply Green das exklusive Vertriebsrecht für die proprietäre Lieferplattform Kanabo VapePod® und Rezepturen über dessen Vertriebsnetz.
- [PRESSWIRE] SECAUCUS, N.J., April 21, 2020 — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has begun to perform antibody testing for coronavirus (COVID-19) using blood samples. With the new service, Quest Diagnostics now provides healthcare providers in the United States access to COVID-19 antibody as well as molecular diagnostic laboratory testing.
- [PRESSWIRE] Vienna – 4 June, 2020 — The Austrian biotech company CEBINA GmbH announces that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic. This seed funding will support proof-of-concept studies of the vaccine that will allow progress to pre-clinical development, scheduled for Q1/2021. The funds are provided by the Blom Family Office.
- [PRESSWIRE] Vienna – 2nd June 2020 — Eveliqure Biotechnologies today, announces that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E. coli (ETEC).
- [PRESSWIRE] Luxembourg – 14 May, 2020 — The pandemic has taken the medical world by surprise and challenged the medical device industry, putting a heavy strain on manufacturers. How does a CEO juggle between the intensifying demand for reliable medical equipment, the need for innovations, and the safety of his employees to make sure that COVID-19 is behind us in the shortest time possible?
- [PRESSWIRE] Austria – 20 April, 2020 — Austrian biotech company Calyxha Biotechnologies GmbH is pleased to announce the grant of European Patent No. EP3383381. This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.
- [PRESSWIRE] Chicago, IL United States – 19 March, 2020 — Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care.
- [PRESSWIRE] Italy – 23 January, 2020 — “During the medical training at the University the students should receive mandatory information about human nutrition in its three different domains, including basic nutrition, applied or public health nutrition and clinical nutrition”, as indicated in the “Manifesto for the Implementation of Nutrition Education” just released in Nice during the ESPEN-NEMS meeting.
- [PRESSWIRE] – Parma – February 18, 2019 — Results bear one clear key message: good treatment is important! Patients in whom the acidosis had been properly controlled by adequate treatment had better growth and better kidney function than those with inadequate treatment.
- [PRESSWIRE] Germany – 17 December, 2018 — The EKHA project “Improving Organ Donation and Transplantation in the EU” will be launched on the European Commission’s Health Policy Platform in 2019, an interactive tool to boost discussions about public health concerns and to share knowledge and best practices.
- [PRESSWIRE] Italy – 9 November, 2018 — Cardioline S.p.A. is pleased to announce the addition of Brian Brenegan as its Chief Executive Officer.
- [PRESSWIRE] Paris – September 12, 2018 — Tattooing has gained tremendous popularity in Western countries. In Australia, Finland France and Germany, approximately 10% of the populations have at least one tattoo [1]. The ‘tattoo craze’ is particularly strong among the young generation, in which every third or fourth person has a tattoo.
- [PRESSWIRE] Paris – September 12, 2018 — The sun is one of the most dangerous carcinogens, yet people who work outdoors are inadequately protected. Since 2014, data on the UV exposure of outdoor workers (such as farmers, road workers, seasonal harvest workers, building workers, roofers, etc.) have been collected in Germany as part of the GENESIS-UV project – with alarming results.
- [PRESSWIRE] Paris – September 12, 2018 — Psoriasis is a chronic, non-communicable skin disease characterized by bright, silvery-white scales on reddened (inflamed) patches of skin, mainly on the arms and legs, the scalp, but also on many other areas of the body, including the genitals.
